SG11201600979SA - Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor - Google Patents
Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitorInfo
- Publication number
- SG11201600979SA SG11201600979SA SG11201600979SA SG11201600979SA SG11201600979SA SG 11201600979S A SG11201600979S A SG 11201600979SA SG 11201600979S A SG11201600979S A SG 11201600979SA SG 11201600979S A SG11201600979S A SG 11201600979SA SG 11201600979S A SG11201600979S A SG 11201600979SA
- Authority
- SG
- Singapore
- Prior art keywords
- methyl
- furo
- thiazol
- hexahydro
- ethynyl
- Prior art date
Links
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 title 1
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 title 1
- 229940094664 Cysteine protease inhibitor Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1314503.2A GB201314503D0 (en) | 2013-08-13 | 2013-08-13 | Cysteine protease inhibitor salt |
PCT/EP2014/067374 WO2015022385A1 (en) | 2013-08-13 | 2014-08-13 | Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201600979SA true SG11201600979SA (en) | 2016-03-30 |
Family
ID=49262126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201600979SA SG11201600979SA (en) | 2013-08-13 | 2014-08-13 | Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor |
Country Status (17)
Country | Link |
---|---|
US (1) | US9650388B2 (ko) |
EP (1) | EP3033345B1 (ko) |
JP (1) | JP6530752B2 (ko) |
KR (1) | KR102271944B1 (ko) |
CN (1) | CN105612160B (ko) |
AU (1) | AU2014307850B8 (ko) |
BR (1) | BR112016003169B1 (ko) |
CA (1) | CA2920797C (ko) |
EA (1) | EA032409B1 (ko) |
GB (1) | GB201314503D0 (ko) |
HK (1) | HK1218915A1 (ko) |
MX (1) | MX369144B (ko) |
MY (1) | MY180170A (ko) |
SG (1) | SG11201600979SA (ko) |
TW (1) | TWI648278B (ko) |
WO (1) | WO2015022385A1 (ko) |
ZA (1) | ZA201600952B (ko) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0817425D0 (en) * | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
GB0817424D0 (en) * | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
IN2012DN04914A (ko) * | 2009-12-10 | 2015-09-25 | Medivir Uk Ltd |
-
2013
- 2013-08-13 GB GBGB1314503.2A patent/GB201314503D0/en not_active Ceased
-
2014
- 2014-08-13 MY MYPI2016700494A patent/MY180170A/en unknown
- 2014-08-13 CA CA2920797A patent/CA2920797C/en active Active
- 2014-08-13 EA EA201690373A patent/EA032409B1/ru not_active IP Right Cessation
- 2014-08-13 BR BR112016003169-5A patent/BR112016003169B1/pt active IP Right Grant
- 2014-08-13 KR KR1020167006445A patent/KR102271944B1/ko active IP Right Grant
- 2014-08-13 EP EP14750516.8A patent/EP3033345B1/en active Active
- 2014-08-13 JP JP2016533918A patent/JP6530752B2/ja active Active
- 2014-08-13 TW TW103127853A patent/TWI648278B/zh active
- 2014-08-13 US US14/911,992 patent/US9650388B2/en active Active
- 2014-08-13 WO PCT/EP2014/067374 patent/WO2015022385A1/en active Application Filing
- 2014-08-13 CN CN201480055170.8A patent/CN105612160B/zh active Active
- 2014-08-13 MX MX2016001978A patent/MX369144B/es active IP Right Grant
- 2014-08-13 AU AU2014307850A patent/AU2014307850B8/en active Active
- 2014-08-13 SG SG11201600979SA patent/SG11201600979SA/en unknown
-
2016
- 2016-02-11 ZA ZA2016/00952A patent/ZA201600952B/en unknown
- 2016-06-16 HK HK16106955.2A patent/HK1218915A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
MX369144B (es) | 2019-10-30 |
EA201690373A1 (ru) | 2016-07-29 |
US9650388B2 (en) | 2017-05-16 |
KR102271944B1 (ko) | 2021-07-02 |
WO2015022385A1 (en) | 2015-02-19 |
AU2014307850B8 (en) | 2017-03-02 |
ZA201600952B (en) | 2017-07-26 |
EP3033345B1 (en) | 2017-07-26 |
MY180170A (en) | 2020-11-24 |
US20160194334A1 (en) | 2016-07-07 |
CN105612160B (zh) | 2017-11-24 |
CA2920797C (en) | 2021-06-15 |
JP2016530260A (ja) | 2016-09-29 |
EP3033345A1 (en) | 2016-06-22 |
AU2014307850A8 (en) | 2017-03-02 |
BR112016003169A2 (ko) | 2017-08-01 |
CN105612160A (zh) | 2016-05-25 |
HK1218915A1 (zh) | 2017-03-17 |
JP6530752B2 (ja) | 2019-06-12 |
MX2016001978A (es) | 2017-01-26 |
BR112016003169B1 (pt) | 2023-02-23 |
KR20160042107A (ko) | 2016-04-18 |
AU2014307850B2 (en) | 2017-02-02 |
AU2014307850A1 (en) | 2016-03-03 |
TWI648278B (zh) | 2019-01-21 |
GB201314503D0 (en) | 2013-09-25 |
EA032409B1 (ru) | 2019-05-31 |
TW201536788A (zh) | 2015-10-01 |
CA2920797A1 (en) | 2015-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY180083A (en) | Tetrahydropyrrolothiazine compounds | |
NZ727601A (en) | Dihydropyrimido fused ring derivative as hbv inhibitor | |
ZA201903093B (en) | Crystalline forms of a magl inhibitor | |
IL245585B (en) | Crystalline form of the hcl salt of a compound for suppressing the reproduction of influenza viruses and methods of production of the crystalline form thereof | |
WO2014132270A3 (en) | Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof | |
EP3619208C0 (en) | CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND | |
JO3318B1 (ar) | مثبطات bace | |
MA39866A (fr) | Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle | |
MX2015015841A (es) | Compuestos de fenoxietil dihidro-1h-isoquinolina. | |
MX2020003020A (es) | Compuestos de aminocarbonilcarbamato. | |
PH12019500875A1 (en) | Pyridone compound as c-met inhibitor | |
MX2022009281A (es) | Inhibidores de rorgamma. | |
EP3371196A4 (en) | HETEROCYCLIC COMPOUNDS AS THROMBOZYTE AGGREGATION INHIBITORS | |
MY176508A (en) | Anti-enterovirus 71 thiadiazolidine derivative | |
ZA201600952B (en) | Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor | |
EA201690593A1 (ru) | Новые соединения мочевины | |
HK1252841A1 (zh) | 噻吩並嘧啶化合物的鹽酸鹽的結晶形式 | |
IN2013MU00777A (ko) | ||
EP3708165A4 (en) | CRYSTAL FORM I OF A 5-AMINOPYRAZOLE CARBOXAMIDE COMPOUND AS A BTK INHIBITOR |